<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>Updated details on Ongoing Clinical Trials in COVID-19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="middle" align="center" rowspan="1" colspan="1">Study</th>
    <th valign="middle" align="center" rowspan="1" colspan="1">Drug</th>
    <th valign="middle" align="center" rowspan="1" colspan="1">Status</th>
    <th valign="middle" align="center" rowspan="1" colspan="1">Organization</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Ongoing Clinical Trials for the Management of the COVID-19 Pandemic</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Umifenovir, triazavirin, baloxavir marboxil, danoprevir/ritonavir, azvudine, sofosbuvir/ledipasvir, sofosbuvir/ daclatasvir, darunavir/cobicistat, and emtricitabine/tenofovir; dexamethasone; methylprednisolone; ASC09 and oseltamivir ixekizumab; bevacizumab</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">China, Iran, Spain, UK</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734
     <sup>TM</sup>) in Participants with Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
    </td>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Remdesivir</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Hoag Memorial Hospital Presbyterian Newport Beach, California, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Stanford Hospital, Stanford, California, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">3. Providence Regional Medical left Everett, Everett, Washington, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Fingolimod in COVID-19</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Fingolimod 0.5 mg</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Wan-Jin Chen Fuzhou, China</td>
   </tr>
   <tr>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">The Clinical Study of Carrimycin on Treatment Patients With COVID-19</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Carrimycin</td>
    <td rowspan="2" valign="top" align="center" colspan="1">Not yet recruiting</td>
    <td rowspan="2" valign="top" align="center" colspan="1">-</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Lopinavir/ritonavir tablets or Arbidol or Chloroquine phosphate</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Efficacy and Safety of Corticosteroids in COVID-19</td>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Methylprednisolone</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Hubei province hospital of integrated Chinese &amp; Western Medicine Wuhan, Hubei, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Yichang first people's Hospital Yichang, Hubei, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">3. Renmin Hospital of Wuhan UniversityWuhan, China</td>
   </tr>
   <tr>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</td>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Sarilumab</td>
    <td rowspan="2" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Regeneron Study Site</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">New York, New York, United States</td>
   </tr>
   <tr>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Mild/Moderate 2019-nCoV Remdesivir RCT</td>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Remdesivir</td>
    <td rowspan="2" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Jin Yin-tan hospital</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Wu Han, Hubei, China</td>
   </tr>
   <tr>
    <td rowspan="4" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Adaptive COVID-19 Treatment Trial</td>
    <td rowspan="4" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Remdesivir</td>
    <td rowspan="4" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. National Institutes of Health - Clinical left, National Institute of Allergy and Infectious Diseases Laboratory of Immunoregulation, Clinical Research SectionBethesda, Maryland, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. University of Nebraska Medical left - Infectious DiseasesOmaha, Nebraska, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">3. University of Texas Medical Branch - Division of Infectious DiseaseGalveston, Texas, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">4. Providence Sacred Heart Medical leftSpokane, Washington, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Ongoing Clinical Trials for the Management of the COVID-19 Pandemic</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Thymosin; suramin; conventional treatment + adalimumab</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Severe 2019-nCoV Remdesivir RCT</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Remdesivir</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Bin Cao; Beijing, Beijing, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Nitric Oxide Gas</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Efficacy and Safety of IFN-a2b in the Treatment of Novel Coronavirus Patients</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Recombinant human interferon α1β</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. ASC09/ritonavir group</td>
    <td rowspan="2" valign="top" align="center" colspan="1">Not yet recruiting</td>
    <td rowspan="2" valign="top" align="center" colspan="1">-</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Lopinavir/ritonavir group</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">mRNA-1273</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious DiseasesSeattle, Washington, United States</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Severe Coronavirus Disease (COVID-19)</td>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Remdesivir</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Hoag Memorial Hospital PresbyterianNewport Beach, California, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Stanford Hospital, Stanford, California, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">3. Providence Regional Medical left Everett, Everett, Washington, United States</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Lopinavir/ritonavir</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">University of Hong Kong, Queen Mary Hospital</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Ribavirin</td>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Hong Kong, Hong Kong</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">3. Interferon Beta-1B</td>
   </tr>
   <tr>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multileft randomized controlled clinical study</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Chloroquine</td>
    <td rowspan="2" valign="top" align="center" colspan="1">-</td>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">The Fifth Affiliated Hospital Sun Yat-Sen University</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Lopinavir/ Ritonavir</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">A prospective, randomized, open-label, parallel controlled trial for the preventive effect of hydroxychloroquine on medical personnel after exposure to COVID-19</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Hydroxychloroquine</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Renmin Hospital of Wuhan University</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients with Severe Acute Respiratory Failure</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Methylprednisolone</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Medical ICU,Peking Union Medical College HospitalBeijing, Beijing, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">The efficacy and safety of carrimycin treatment in patients with novel coronavirus infectious disease (COVID-19): a multileft, randomized, open- label controlled trial</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Carrimycin</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Beijing You'an Hospital, Capital Medical University</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">recombinant human interferon alpha 1b</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Chinese PLA General Hospital</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">A Pilot Study of Sildenafil in COVID-19</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Sildenafil citrate</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Department and Institute of Infectious Disease, Wuhan, Hubei, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Hydroxychloroquine</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">The Second Affiliated Hospital of Chongqing Medical University</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">The Efficacy and Safety of Thalidomide Combined with Low-dose Hormones in the Treatment of Severe COVID-19</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Thalidomide</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquine for Treatment of COVID19: A Randomized Control Trial</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Oral</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Subsai Kongsaengdao, Bangkok, Thailand</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization</td>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Losartan</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Not yet recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Hennepin County Medical left, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">M Health Fairview University of Minnesota Medical left, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">University of Minnesota, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Chloroquine</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus Disease 2019</td>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Favipiravir Combined with Tocilizumab</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Guiqiang Wang, Beijing, Beijing, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Peking University First Hospital, Beijing, Beijing, China</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Trial of Treatments for COVID-19 in Hospitalized Adults</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Remdesivir</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Not yet recruiting</td>
    <td rowspan="3" valign="top" align="center" colspan="1">-</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">2. Lopinavir/ritonavir</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">3. Interferon Beta-1A</td>
   </tr>
   <tr>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization</td>
    <td rowspan="3" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Losartan</td>
    <td rowspan="3" valign="top" align="center" colspan="1">Not yet recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Hennepin County Medical left, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">M Health Fairview University of Minnesota Medical left, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">University of Minnesota, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients with Mild Coronavirus Disease (COVID-19)</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">1. Lopinavir/ritonavir Hydroxychloroquine sulfate</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Asan Medical left, University of Ulsan College of Medicine, Seoul, Korea, Republic of Korea</td>
   </tr>
   <tr>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Evaluation of Ganovo (Danoprevir) Combined with Ritonavir in the Treatment of Novel Coronavirus Infection</td>
    <td rowspan="2" valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" colspan="1">Ganovo with ritonavir +/-Interferon</td>
    <td rowspan="2" valign="top" align="center" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">The Ninth Hospital of Nanchang</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Nanchang, Jiangxi, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Eculizumab (Soliris) in Covid-19 Infected Patients</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Eculizumab</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Initiated</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Norwegian Coronavirus Disease 2019 Study</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Hydroxychloroquine Sulfate</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Not yet recruiting</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Post-exposure Prophylaxis for SARS-Coronavirus-2</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Hydroxychloroquine</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">University of Minnesota, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">The efficacy and safety of pirfenidone capsules in the treatment of severe new coronavirus pneumonia (COVID-19)</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Pirfenidone</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Third Xiangya Hospital of Central South University</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Oseltamivir</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Recruiting</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Zhongnan Hospital of Wuhan University in Wuhan, China</td>
   </tr>
   <tr>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Expanded Access Remdesivir (RDV; GS-5734TM)</td>
    <td valign="top" align="left" style="padding-left: 15px; text-indent: -15px;" rowspan="1" colspan="1">Remdesivir</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Initiated</td>
    <td valign="top" align="center" rowspan="1" colspan="1">-</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="t2fn1">
   <p>The table represents a list of selected clinical trials for the amelioration of COVID-19 specific drugs and vaccines.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
